Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06877208
Active, not recruiting Not applicable

The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans

NCT06877208 · tracked via the Priya Life Science Denmark tracker
Sponsor
Nicolai Jacob Wewer Albrechtsen
Phase
Not applicable
Started
2025-03-18
Last updated
2026-04-29

Condition(s) studied

Cerebral Glucose Metabolism

Investigational drug(s) / intervention(s)

Glucagon (part C)Glucose clamp (part C)Saline (part C)Glucagon (part D)Glucose clamp (part D)Saline (part D)

Glucagon (part C): 90 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).

Glucose clamp (part C): 90 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).

Saline (part C): 90 minutes intravenous infusion with isotonic NaCl.

Glucagon (part D): 210 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).

Glucose clamp (part D): 210 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).

Saline (part D): 210 minutes intravenous infusion with isotonic NaCl.

Study summary

This is a pilot study in which the investigators will investigate the effect of exogenous glucagon on cerebral glucose metabolism in healthy humans.

Participants will participate in either part C or part D of the study, and each participant will participate in three study days. During a study day the participant will receive an intravenous infusion of either glucagon, glucose (in an adjustable rate to match to glucose concentrations achieved with the glucagon infusion) or saline. During each study day an 18F-flouro-deoxy-glucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) scan will be performed to quantify cerebral glucose metabolism during the first part (acute effect) of the glucagon/glucose/saline infusion (part C) or the last part (later effect) of the glucagon/glucose/saline infusion (part D).

Eligibility

Sex
ALL
Min age
55 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 55 to 70 years * BMI under or equal to 30 kg/m2 * Capable of understanding the participant information and signing the consent form Exclusion Criteria: * Enrolment in other research projects that might interfere with the study * Diabetes diagnosis (type 1 and 2) * Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol * Diagnosis of psychiatric disorders, dementias, or any other neurological disorders that in the opinion of the investigator precludes compliance with the study protocol, evaluation of the results or represents an unacceptable risk for the participants safety * Severe claustrophobia * Impaired liver og kidney function * Cardiac problems including any of the following: 1. Classified as being in New York Heart Association (NYHA) class III or IV 2. Angina pectoris (chest pain) within the last 6 months 3. Acute myocardial infarction (heart attack) within last 2 years * Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic. * Active or recent malignant disease * Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement * Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol

Primary outcome measure(s)

  • Cerebral metabolic rate of glucose (CMRglc), acute effect (part C) — 15-55 minutes
    CMRglc is calculated based on the 18F-FDG PET/CT scan.

Trial sites (1)

FacilityCityRegionStatus
Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark Copenhagen Denmark

More Nicolai Jacob Wewer Albrechtsen trials in Denmark

Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants Starting soon
Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans Recruiting

Other trials for the same condition

Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06877208 on ClinicalTrials.gov ↗ ← All trials in Denmark